Related Experiment Videos
Pulmonary fibrosis associated with low-dose adjuvant methyl-CCNU
M Block1, R M Lachowiez, C Rios
1Regional Cancer Center, Lourdes Hospital, Binghamton, New York.
Medical and Pediatric Oncology
|January 1, 1990
Abstract:
Pulmonary fibrosis is a serious side effect of nitrosourea therapy, occurring most frequently in patients treated with BCNU. Pulmonary fibrosis developed in a 63 year-old male patient while being treated with adjuvant methyl-CCNU for rectal carcinoma. This toxicity is rare with methyl-CCNU, having only been reported once previously. The case of methyl-CCNU-induced pulmonary fibrosis reported here occurred at a much lower total dose than the first reported case (604 mg/m2 vs. 2,733 mg/m2). Details of the case history, including radiographic and pathologic findings, are presented.